1-20 of 114
Nirav N. Shah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Timothy S. Fenske, Xin Victoria Wang, Brian G. Till, Kristie A. Blum, Matthew Lunning, Hillard M. Lazarus, Paul A.S. Fishkin, Lale Kostakoglu Shields, David W. Scott, Ann S. LaCasce, Patrick B. Johnston, Amanda F. Cashen, Leslie L. Popplewell, Robert M. Dean, Nausheen Ahmed, Nirav N. Shah, Nina D. Wagner-Johnston, Boyu Hu, Bhagirathbhai R. Dholaria, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl
Journal: Blood
Blood (2024) 144 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2024-212973
Published: 2024
Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Kritika Yadav, Tanvi H. Patel, Ramya Bachu, Jean Esselmann, Lisa E Rein, Aniko Szabo, Abhishek Janardan, Evanka Annyapu, Catherine E. Skoog, Areyl Goff, Othman Salim Akhtar, Samer Al Hadidi, Sharmilan Thanendrarajan, Maurizio Zangari, Nirav N. Shah, Frits van Rhee, Mehdi Hamadani, Binod Dhakal, Anita D'Souza, Meera Mohan, Carolina Schinke
Journal: Blood
Blood (2024) 144 (Supplement 1): 254.
https://doi.org/10.1182/blood-2024-210725
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps, Peter A. Riedell, Herbert A. Eradat, Saad S. Kenderian, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Scott R. Solomon, Daniel A. Ermann, Jon E. Arnason, Abhinav Deol, Tatyana Feldman, Charalambos Andreadis, Monalisa Ghosh, Shuo Ma, Stephen J. Schuster, Usama Gergis, Julie M. Vose, Jacob D. Soumerai, Koen van Besien, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 887.
https://doi.org/10.1182/blood-2024-200339
Published: 2024
Journal Articles

Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study

Nirav N. Shah, Zulfa Omer, Graham P. Collins, Francesco Forconi, Alexey Danilov, John C. Byrd, Dima El-Sharkawi, Emma Searle, Alvaro J Alencar, Shuo Ma, Sarah Injac, Talha Munir
Journal: Blood
Blood (2024) 144 (Supplement 1): 884.
https://doi.org/10.1182/blood-2024-194839
Published: 2024
Journal Articles

Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Na Hyun Kim, Fatima Khamissi, Kathleen Bone, Nathan Kopp, Walter Longo, Bryon D. Johnson, Tyce Kearl, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah
Journal: Blood
Blood (2024) 144 (Supplement 1): 3459.
https://doi.org/10.1182/blood-2024-205752
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004

Tanya Siddiqi, Jordan Gauthier, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob D. Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Charalambos Andreadis, Daniel A. Ermann, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, William G. Wierda
Journal: Blood
Blood (2024) 144 (Supplement 1): 4633.
https://doi.org/10.1182/blood-2024-200840
Published: 2024
Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani
Journal: Blood
Blood (2024) 144 (Supplement 1): 1039.
https://doi.org/10.1182/blood-2024-200832
Published: 2024
Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Matthew J. Cortese, MD, MPH, Megan M Herr, Nisha Nair, Jason Romancik, Natalie Grover, Rahul S Bhansali, Colin Thomas, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, James A Davis, Christy Jesme, Ari Pelcovits, Megan Melody, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alex Niu, Alexey V. Danilov, Nirav N. Shah, Deborah M. Stephens, Jonathon B. Cohen, Leo I. Gordon, Stefan K. Barta, Narendranath Epperla, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 525.
https://doi.org/10.1182/blood-2024-212106
Published: 2024
Journal Articles

Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Nirav N. Shah, Richard T. Maziarz, Caron A. Jacobson, Patrick B. Johnston, Sunil Abhyankar, Iris Isufi, Miguel Angel Perales, Monalisa Ghosh, Matthew Ulrickson, Allison C. Rosenthal, Javier L. Munoz, Nancy M. Hardy, Aaron P. Rapoport, Reem Karmali, Farrukh T. Awan, Matthew Stuart McKinney, Mitchell Horwitz, Matthew Lunning, Nathan Denlinger, Marek Ancukiewicz, Madhavi Nallewar, Kimberly C Coleman, Esther Eromosele, Remigiusz Kaleta, Johanna Theruvath, Anna Wijatyk, David B. Miklos
Journal: Blood
Blood (2024) 144 (Supplement 1): 68.
https://doi.org/10.1182/blood-2024-208539
Published: 2024
Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Peter A. Riedell, Mi Kwon, Ian W. Flinn, Michael J. Dickinson, Carlos Solano, Ulrich Jaeger, Javier Briones, Koji Kato, Shaun Fleming, Emmanuel Bachy, Alessandro Rambaldi, Leyla O. Shune, Nirav N. Shah, Didier Blaise, Matthew J. Frigault, Aravind Ramakrishnan, Anne Yang, David Pearson, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
Journal: Blood
Blood (2024) 144 (Supplement 1): 67.
https://doi.org/10.1182/blood-2024-204264
Published: 2024
Journal Articles

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Nirav N. Shah, Aniko Szabo, Tyce Kearl, Dina Schneider, Walter Longo, Bryon D. Johnson, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske
Journal: Blood
Blood (2024) 144 (Supplement 1): 3448.
https://doi.org/10.1182/blood-2024-200899
Published: 2024
Journal Articles

Pirtobrutinib in Patients with Mantle Cell Lymphoma: A Real-World Study in the United States

Nirav N. Shah, Katherine B. Winfree, Naleen Raj Bhandari, Qinli Ma, Dan He, Sarang Abhyankar, Lisa M. Hess
Journal: Blood
Blood (2024) 144 (Supplement 1): 7799.
https://doi.org/10.1182/blood-2024-199667
Published: 2024
Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Adam J. Olszewski, Mariana Bastos-Oreiro, Sarit E. Assouline, Izidore S. Lossos, Catherine Diefenbach, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Nirav N. Shah, Ronan Foley, Daniel J Hodson, Sneha Makadia, Song Pham, Elicia Penuel, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde
Journal: Blood
Blood (2024) 144 (Supplement 1): 989.
https://doi.org/10.1182/blood-2024-194581
Published: 2024
Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Brandon L Ellsworth, Megan Melody, Narendranath Epperla, Natalie Grover, Jason T Romancik, Matthew J Cortese, Rahul S Bhansali, Tamara K Moyo, Vaishalee P Kenkre, Thomas Ollila, Brian Hess, Lindsey Fitzgerald, Geoffrey Shouse, Matthew Matasar, Kaitlin Annunzio, Megan M Herr, James A Davis, Christy Jesme, Ari Pelcovits, Jonathan Moreira, Adam Yuh Lin, Shuo Ma, Jane N Winter, Alexey V. Danilov, Nirav N. Shah, Stefan K. Barta, Jonathon B Cohen, Leo I. Gordon, Deborah M. Stephens, Reem Karmali
Journal: Blood
Blood (2024) 144 (Supplement 1): 612.
https://doi.org/10.1182/blood-2024-202665
Published: 2024
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies

Nitin Jain, Catherine C. Coombs, James D'Olimpio, Nirav N. Shah, Jacqueline C. Barrientos, Seung Tae Lee, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William G. Wierda, Varsha Gandhi, Javier Pinilla-Ibarz
Journal: Blood
Blood (2024) 144 (Supplement 1): 1866.
https://doi.org/10.1182/blood-2024-208549
Published: 2024
Journal Articles

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Gulrayz Ahmed, Amer Al Homssi, Ramsha Ahmed, Walter Longo, Nirav N. Shah, Lyndsey Runaas, Marcelo C. Pasquini, Timothy S. Fenske, Lisa E Rein, Aniko Szabo, Mehdi Hamadani, Sameem Abedin
Journal: Blood
Blood (2024) 144 (Supplement 1): 7346.
https://doi.org/10.1182/blood-2024-209225
Published: 2024
Journal Articles

Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL

Adam Kidwell, Fateeha Furqan, Emilie Aschenbrenner, Walter Longo, Sumana Devata, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah
Journal: Blood
Blood (2024) 144 (Supplement 1): 2374.
https://doi.org/10.1182/blood-2024-203974
Published: 2024
Journal Articles

Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

Peter A. Riedell, Krish Patel, Vanessa Dunleavy, Yasmin H. Karimi, Nirav N. Shah, Vincent Ribrag, Loic Ysebaert, Robin Noel, Gabriel Brisou, Justin Kline, Chet Bohac, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nancy Chen, Jean-Marie Michot, Benoîtt Tessoulin, Sairah Ahmed
Journal: Blood
Blood (2024) 144 (Supplement 1): 4497.
https://doi.org/10.1182/blood-2024-203668
Published: 2024
Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Clinical Trials & Observations
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (13): 1374–1386.
https://doi.org/10.1182/blood.2024024510
Published: 2024
Includes: Supplemental data